The Maxpar Direct Immune Profiling System could lower the threshold to doing mass cytometry due to ease of use, a core lab director said.
Revenues from mass cytometry instruments, consumables, and service increased 48 percent to $19.1 million from $12.9 million in Q4 2017.
The company said it saw the biggest revenue growth in its instruments business, which gained 32 percent year over year.
Using the publicly available ImmPort database, researchers standardized and analyzed immune-related data for more than 10,300 healthy individuals.
The companies will jointly promote Visiopharm's Phenomap image-analysis software alongside Fluidigm's Hyperion imaging system and related products.
Fueled by an NIH SBIR grant, analytics firm Cytobank is building out its machine-learning algorithms and adding pipelines to support big-picture research.
Fluidigm reported that its mass cytometry revenues jumped 32 percent while genomics revenues fell 5 percent year over year.
A 30 percent decrease in instrument revenue was tempered by a 23 percent uptick in consumables revenue.
Using a mass cytometry method called EpiTOF, researchers profiled histone modifications and variants in a range of immune cell types across individuals of different ages.
At the AACR annual meeting, researchers highlighted genomics- and proteomics-informed research aimed at establishing more effective, targeted immunotherapies.
The Oregon state Senate unanimously passed a bill that would make it easier for people convicted of crimes to initiate DNA testing of evidence, according to the Associated Press.
People reports that researchers have uncovered genetic variants that lead people to always feel full.
Florida state senators are to weigh a bill prohibiting life insurance companies from using genetic information in coverage decisions, according to Florida Politics.
In Genome Research this week: metagenomic sequencing assay that detects pathogens in cerebrospinal fluid, single-tube long fragment read approach, and more.